Home / Letter From The Editor / Dec. 3, 2019

Dec. 3, 2019

Dec 3, 2019
 

Many, many times we have had features on the SGLT-2 inhibitors since the first one was introduced in 2013. We have watched as the research has continued, and we have learned that these medications work to lower blood glucose levels, weight and cardiovascular risk. This week we look more at the reasons why this may be happening, and how we can add renal protectivity to the mix.

Onyi Ibeji, PharmD. Candidate, and Amber Satz, PharmD Candidate, both from LECOM School of Pharmacy, are presenting SGLT-2 Inhibitor related articles that focus on the renal issues and how these drugs may correct a problem that often goes untreated in diabetes patients.

 

 

Dave Joffe

Editor-in-chief